PT2367561E - Composições e métodos para o tratamento da doença celíaca - Google Patents

Composições e métodos para o tratamento da doença celíaca Download PDF

Info

Publication number
PT2367561E
PT2367561E PT98284532T PT09828453T PT2367561E PT 2367561 E PT2367561 E PT 2367561E PT 98284532 T PT98284532 T PT 98284532T PT 09828453 T PT09828453 T PT 09828453T PT 2367561 E PT2367561 E PT 2367561E
Authority
PT
Portugal
Prior art keywords
compositions
treatment
methods
celiac disease
celiac
Prior art date
Application number
PT98284532T
Other languages
English (en)
Inventor
Robert Paul Anderson
Jessica Anne Stewart
James Anthony Dromey
Jason Allan Tye-Din
Original Assignee
Immusant Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immusant Inc filed Critical Immusant Inc
Publication of PT2367561E publication Critical patent/PT2367561E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
PT98284532T 2008-11-30 2009-11-30 Composições e métodos para o tratamento da doença celíaca PT2367561E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11864308P 2008-11-30 2008-11-30

Publications (1)

Publication Number Publication Date
PT2367561E true PT2367561E (pt) 2015-10-23

Family

ID=42225141

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98284532T PT2367561E (pt) 2008-11-30 2009-11-30 Composições e métodos para o tratamento da doença celíaca

Country Status (16)

Country Link
US (5) US8835603B2 (pt)
EP (3) EP3269379A1 (pt)
JP (2) JP5851243B2 (pt)
CN (2) CN102438643B (pt)
AU (1) AU2009321481B2 (pt)
BR (1) BRPI0922122A2 (pt)
CA (2) CA2744787C (pt)
DK (2) DK2977053T3 (pt)
ES (2) ES2549481T3 (pt)
HK (3) HK1162918A1 (pt)
HR (1) HRP20150873T1 (pt)
HU (1) HUE027237T2 (pt)
MX (1) MX346450B (pt)
NZ (1) NZ593474A (pt)
PT (1) PT2367561E (pt)
WO (1) WO2010060155A1 (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
US10105437B2 (en) * 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
MXPA06012322A (es) 2004-04-28 2007-01-31 Btg Int Ltd Epitopes relacionados con enfermedad celiaca.
EP3269379A1 (en) 2008-11-30 2018-01-17 Immusant, Inc. Compositions and methods for treatment of celiac disease
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
WO2012021512A2 (en) 2010-08-10 2012-02-16 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
EP2666017B1 (en) * 2011-01-20 2018-10-03 Cyrex Laboratories, LLC Methods and apparatus for detection of gluten sensitivity, and its differentiation from celiac disease
ITRM20110487A1 (it) * 2011-09-19 2013-03-20 Consiglio Per La Ricerca E La Speri Mentazione In Peptidi aventi effetto protettivo nei confronti della attività infiammatoria del peptide 31-43 della a-gliadina nella malattia celiaca.
ES2402286B1 (es) * 2011-09-29 2014-03-04 Universidad De Valladolid Péptido inmunogénico del gluten y sus aplicaciones.
EP2812344A4 (en) 2012-02-07 2015-10-28 Vibrant Holdings Llc SUBSTRATE, PEPTIDARRAYS AND METHOD
CN110064049B (zh) 2012-06-21 2024-02-09 西北大学 肽缀合粒子
US10006909B2 (en) 2012-09-28 2018-06-26 Vibrant Holdings, Llc Methods, systems, and arrays for biomolecular analysis
US10286376B2 (en) 2012-11-14 2019-05-14 Vibrant Holdings, Llc Substrates, systems, and methods for array synthesis and biomolecular analysis
CA2932532C (en) 2012-12-04 2021-06-22 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
EP3494966B1 (en) 2013-03-13 2024-04-03 onCOUR Pharma, Inc. Immune-modifying particles for the treatment of inflammation
AU2014240046A1 (en) * 2013-03-14 2015-10-08 Robert P. Anderson Placebo-controlled gluten challenge method
WO2014182897A2 (en) * 2013-05-08 2014-11-13 Jm Biologicals Compositions and methods for the production of gluten free food products
KR102485789B1 (ko) * 2013-08-13 2023-01-05 노쓰웨스턴유니버시티 펩티드-접합된 입자
EP3043812A1 (en) * 2013-09-10 2016-07-20 Immusant Inc. Dosage of a gluten peptide composition
EP3046576A4 (en) * 2013-09-20 2017-07-12 Immusant Inc. Compositions and methods related to oat sensitivity
EP3909603A1 (en) 2014-02-21 2021-11-17 Ecole Polytechnique Fédérale de Lausanne (EPFL) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
AU2015249592A1 (en) * 2014-04-24 2016-12-15 Immusant, Inc. Use of Interleukin-2 for diagnosis of Celiac disease
CA2960655C (en) 2014-09-10 2024-03-19 Vibrant Holdings, Llc Peptide microarrays and novel biomarkers for celiac disease
WO2016054038A1 (en) * 2014-09-29 2016-04-07 Immusant, Inc. Use of hla genetic status to assess or select treatment of celiac disease
CN107531767A (zh) * 2014-11-21 2018-01-02 免疫桑特公司 用于在治疗和诊断1型糖尿病中使用的肽
KR101736744B1 (ko) 2014-12-03 2017-05-17 주식회사 한국유전자정보연구원 셀리악병 진단용 프라이머 세트와 이를 이용한 셀리악병 진단방법
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017058074A1 (en) * 2015-08-30 2017-04-06 Diamyd Medical Ab Combination therapy using gliadin and gamma aminobutyric acid
US11510996B2 (en) 2015-12-23 2022-11-29 Cour Pharmaceuticals Development Company Inc. Covalent polymer-antigen conjugated particles
CA3015074C (en) 2016-02-18 2024-05-28 Cour Pharmaceuticals Development Company, Inc. Process for the preparation of tolerizing immune-modulating particles
EP3464322B1 (en) * 2016-06-05 2023-04-05 Tel HaShomer Medical Research Infrastructure and Services Ltd. Novel molecules for the treatment of inflammation
EP3474881A1 (en) 2016-06-28 2019-05-01 Immusant, Inc. Escalating dosage schedules for treating celiac disease
US11166993B2 (en) * 2017-01-12 2021-11-09 Probi Ab Methods for celiac disease using lactobacillus strains
WO2018218250A2 (en) 2017-05-26 2018-11-29 Vibrant Holdings, Llc Photoactive compounds and methods for biomolecule detection and sequencing
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
CA3074839A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
EP3703728A4 (en) * 2017-10-30 2022-01-05 Immusant Inc. DOSING SCHEMES FOR COELIAKIA
JP6568193B2 (ja) 2017-12-19 2019-08-28 ホーユー株式会社 エピトープ
KR20200121300A (ko) * 2018-02-08 2020-10-23 코어 파마슈티칼스 디벨롭먼트 컴퍼니 인크. 관용화 입자를 갖는 소아지방변증의 치료
CN113227124A (zh) * 2018-10-31 2021-08-06 味之素株式会社 具有针对抗体的亲和性物质、切割性部分及反应性基团的化合物或其盐
WO2020181272A1 (en) * 2019-03-06 2020-09-10 Cue Biopharma, Inc. Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof
JP7374687B2 (ja) * 2019-09-26 2023-11-07 三和酒類株式会社 ペンタペプチド化合物
EP4061403A4 (en) * 2019-11-19 2023-12-27 Spark Therapeutics, Inc. SECRETABLE PROTEIN-INDUCED IMMUNE TOLERANCE AND TREATMENT OF AUTOIMMUNE, ALLERGIC AND OTHER DISEASES AND DISORDERS
IL307722A (en) 2021-04-16 2023-12-01 Cour Pharmaceuticals Dev Company Inc A method of monitoring the existence of immunological tolerance
EP4337667A1 (en) 2022-07-21 2024-03-20 Antiva Biosciences, Inc. Compositions and dosage forms for treatment of hpv infection and hpv-induced neoplasia

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740371A (en) 1984-09-17 1988-04-26 International Institute Of Cellular And Molecular Pathology Treatment of allergy
AU595021B2 (en) 1986-03-06 1990-03-22 Commonwealth Scientific And Industrial Research Organisation In vitro assay for detecting cell-mediated immune responses
FR2615622B1 (fr) 1987-05-19 1994-05-06 Ire Medgenix Sa Dosage plasmatique de monokines
US5547669A (en) 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
US5998366A (en) 1990-09-21 1999-12-07 The Regents Of The University Of California Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders
US5674978A (en) 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
IL105153A (en) 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
JPH10511541A (ja) 1994-08-26 1998-11-10 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア Ｔ細胞応答を調節するための方法および組成物
WO1996007428A1 (en) 1994-09-02 1996-03-14 Immulogic Pharmaceutical Corporation Peptide compositions capable of down regulating an antigen specific immune response
US6759234B1 (en) 1994-09-02 2004-07-06 Immulogic Pharmaceutical Corporation Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
US5750356A (en) 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
EP0905518A1 (en) 1997-09-23 1999-03-31 Academisch Ziekenhuis Leiden Peptides specific for gluten-sensitive T-cells and use thereof
US6300308B1 (en) 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
US6667160B2 (en) 2000-03-15 2003-12-23 Kenneth D. Fine Method for diagnosing immunologic food sensitivity
US8110218B2 (en) 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
EP1241476A1 (en) 2001-03-12 2002-09-18 Mabtech AB Diagnosis of metal allergy through cytokine release by T-cells in vitro
WO2002080963A1 (en) 2001-04-05 2002-10-17 Virginia Mason Research Center Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment
EP1377604B1 (en) 2001-04-12 2014-12-31 Academisch Ziekenhuis Leiden Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides
FI20010868A0 (fi) 2001-04-25 2001-04-25 Markku Maeki Menetelmä ja välineet gluteenin indusoimien tautien havaitsemiseksi
WO2003047618A2 (en) 2001-12-05 2003-06-12 Circassia Limited Immunotherapeutic methods and systems
EP1332760A1 (en) 2002-02-04 2003-08-06 Academisch Ziekenhuis Leiden Novel epitopes for celiac disease and autoimmune diseases, methods for detecting those and novel non-antigenic food compounds
AU2003215272B2 (en) 2002-02-14 2008-04-03 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7320788B2 (en) 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
AU2003234597A1 (en) 2002-05-14 2003-12-02 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7202216B2 (en) 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
AU2002952834A0 (en) 2002-09-16 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research A method of treating an autoimmune disease
AU2003277989B2 (en) 2002-11-08 2010-04-22 QIAGEN Australia Holding Pty. Ltd. Diagnostic assay for measuring a cell mediated immune response
AU2002952548A0 (en) 2002-11-08 2002-11-21 Cellestis Limited Diagnostic assay
AU2003294473A1 (en) 2002-11-20 2004-06-15 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for celiac sprue
US7563864B2 (en) * 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
MXPA06012322A (es) * 2004-04-28 2007-01-31 Btg Int Ltd Epitopes relacionados con enfermedad celiaca.
GB0409775D0 (en) 2004-04-30 2004-06-09 Mabtech Ab Assay
CA2585462A1 (en) 2004-10-29 2006-05-11 Benaroya Research Institute At Virginia Mason Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use
WO2007022477A2 (en) 2005-08-17 2007-02-22 Multicell Immunotherapeutics, Inc. Methods and compositions to generate and control the effector profile of t cells
WO2007047303A2 (en) 2005-10-12 2007-04-26 Alvine Pharmaceuticals, Inc. Pegylated glutenase polypeptides
JP2009536157A (ja) 2006-04-13 2009-10-08 ペプチミューン，インコーポレイテッド エピトープ透過性の指向された拡張を介した指向性配列ポリマー組成物の設計方法および合成方法
ES2492468T3 (es) * 2007-01-25 2014-09-09 Actogenix N.V. Tratamiento de enfermedad inmunitaria por administración a través de la mucosa de antígenos usando Lactobacillus genéticamente modificado
ITFE20070003A1 (it) 2007-02-01 2007-05-03 Girolamo Calo' Utilizzo di peptidi ricchi in prolina e glutamina capaci di legarsi alle molecole hla-dq2 e dq8 come "carriers specifici" di agenti capaci di danneggiare o uccidere le cellule che esprimono dette molecole hla nel contesto dell a mucosa enterica di pa
AU2008229636B2 (en) 2007-03-16 2014-08-14 QIAGEN Australia Holding Pty. Ltd. A cell-mediated immune response assay and kits therefor
WO2009131909A2 (en) 2008-04-21 2009-10-29 Bio-Rad Laboratories, Inc. Recombinant deamidated gliadin antigen
WO2009139887A2 (en) 2008-05-16 2009-11-19 The Board Of Trustees Of The Leland Stanford Junior University Non-inflammatory gluten peptide analogues as biomarkers for celiac sprue
JP2011529171A (ja) 2008-07-25 2011-12-01 セレスティス リミテッド 診断方法
EP3269379A1 (en) 2008-11-30 2018-01-17 Immusant, Inc. Compositions and methods for treatment of celiac disease
US20120107847A1 (en) 2009-07-02 2012-05-03 Dsm Ip Assets B.V. Testing efficacy for celiac disease
US9459253B2 (en) 2009-12-23 2016-10-04 Cellestis Limited Assay for measuring cell-mediated immunoresponsiveness
EP2577307B1 (en) 2010-05-28 2019-05-22 Cellestis Limited A diagnostic assay
US20110311536A1 (en) 2010-06-11 2011-12-22 Dana-Farber Cancer Institute, Inc. Prevention of type 1 diabetes by treg vaccination with an insulin mimetope
CN103703375B (zh) 2011-06-29 2018-04-10 塞尔雷斯蒂斯有限公司 具有增强灵敏度的细胞介导免疫应答测定
US20140248251A1 (en) 2011-07-25 2014-09-04 Daniel C. Adelman Methods and Pharmaceutical Compositions for Treating Celiac Disease and Gluten Intolerance
WO2013036302A1 (en) 2011-09-06 2013-03-14 Selecta Biosciences, Inc. Induced tolerogenic dendritic cells for generating cd8+ regulatory t cells
ES2402286B1 (es) 2011-09-29 2014-03-04 Universidad De Valladolid Péptido inmunogénico del gluten y sus aplicaciones.
WO2013085851A2 (en) 2011-12-05 2013-06-13 Bio-Rad Laboratories, Inc. Recombinant deamidated gliadin antigen
AU2014240046A1 (en) 2013-03-14 2015-10-08 Robert P. Anderson Placebo-controlled gluten challenge method
EP3043812A1 (en) 2013-09-10 2016-07-20 Immusant Inc. Dosage of a gluten peptide composition
EP3046576A4 (en) 2013-09-20 2017-07-12 Immusant Inc. Compositions and methods related to oat sensitivity
AU2015249592A1 (en) 2014-04-24 2016-12-15 Immusant, Inc. Use of Interleukin-2 for diagnosis of Celiac disease

Also Published As

Publication number Publication date
US20190048047A1 (en) 2019-02-14
CN105079781B (zh) 2018-07-20
JP6027215B2 (ja) 2016-11-16
MX2011005632A (es) 2011-11-29
US20170158743A1 (en) 2017-06-08
AU2009321481B2 (en) 2014-08-21
MX346450B (es) 2017-03-17
CN102438643A (zh) 2012-05-02
EP2367561B1 (en) 2015-05-20
US20210115096A1 (en) 2021-04-22
AU2009321481A1 (en) 2011-07-07
US9464120B2 (en) 2016-10-11
HK1162918A1 (en) 2012-09-07
ES2549481T3 (es) 2015-10-28
DK2367561T3 (en) 2015-08-24
EP2367561A1 (en) 2011-09-28
JP2016128402A (ja) 2016-07-14
JP5851243B2 (ja) 2016-02-03
US20150050303A1 (en) 2015-02-19
HK1219898A1 (zh) 2017-04-21
CA2744787A1 (en) 2010-06-03
US20110293644A1 (en) 2011-12-01
ES2642096T3 (es) 2017-11-15
HUE027237T2 (en) 2016-10-28
NZ593474A (en) 2013-04-26
CN102438643B (zh) 2015-07-01
HK1249446A1 (zh) 2018-11-02
BRPI0922122A2 (pt) 2017-08-01
CA2744787C (en) 2019-06-11
HRP20150873T1 (hr) 2015-11-06
CA3042826A1 (en) 2010-06-03
EP2977053A1 (en) 2016-01-27
DK2977053T3 (en) 2017-10-09
EP2367561A4 (en) 2012-06-06
EP3269379A1 (en) 2018-01-17
CN105079781A (zh) 2015-11-25
EP2977053B1 (en) 2017-07-05
WO2010060155A1 (en) 2010-06-03
JP2012510431A (ja) 2012-05-10
US8835603B2 (en) 2014-09-16

Similar Documents

Publication Publication Date Title
HK1249446A1 (zh) 用於治療乳糜瀉的組合物和方法
IL258794B (en) Methods and preparations for the diagnosis and treatment of cancer
EP2361089A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE
IL208354A0 (en) Methods of treatment
HK1159498A1 (en) Methods and compositions for the treatment of cancer
ZA201105472B (en) Methods and compositions for diagnosis and treatment of cancer
IL215856A0 (en) Compositions and methods for treatment of cardiovascular disease
ZA201006988B (en) Method and compositions for treatment of cancer
EP2411006A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF RENAL DISORDERS
EP2271352A4 (en) COMPOSITIONS AND METHODS FOR TREATING NEOPLASTIC DISEASE
EP2340027A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
ZA201008201B (en) Novel compositions and methods for treating hyperproliferative diseases
IL214349A0 (en) Compositions and methods for the treatment of cancer
EP2437738A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT
EP2405747A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES
HK1157228A1 (en) Compositions and methods of treating amyloid disease
EP2411031A4 (en) Methods and compositions for the treatment of cancer
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia